Combining two therapies to improve outcomes for liver cancer patients before surgery
A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC Patients
This study is looking at a new treatment that combines two therapies to help boost the immune system in liver cancer patients who are about to have surgery, with the hope of improving their chances of recovery and preventing the cancer from coming back.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11046656 on NIH RePORTER |
What this research studies
This research investigates the use of a combination therapy that blocks two specific pathways in liver cancer patients who are eligible for surgery. The goal is to enhance the immune response against the cancer and reduce the chances of recurrence after surgery. Patients will receive this treatment before their surgical procedure, and researchers will analyze the effects on tumor response and immune system changes. The study aims to identify biomarkers that can predict which patients will benefit most from this approach.
Who could benefit from this research
Good fit: Ideal candidates are patients diagnosed with resectable hepatocellular carcinoma (HCC) who are preparing for surgical resection.
Not a fit: Patients with non-resectable liver cancer or those who have already undergone surgery may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved survival rates and reduced recurrence of liver cancer after surgery.
How similar studies have performed: Preliminary studies have shown promising results with similar approaches, indicating potential for success in this research.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Kaseb, Ahmed — University of Tx Md Anderson Can Ctr
- Study coordinator: Kaseb, Ahmed
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.